Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/203167
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation |
Autor: | Caballero-Velázquez, Teresa CSIC ORCID; Calderón-Cabrera, Cristina CSIC; López-Corral, L.; Puig, Noemi; Márquez-Malaver, Francisco José; Pérez-López, Estefanía; García-Calderón, Clara B. CSIC ORCID; Rosso-Fernández, Clara; Caballero Barrigón, D.; Martín, J.; Mateos, Maria Victoria; San Miguel, Jesús F. CSIC ORCID; Pérez-Simón, José A. CSIC ORCID | Palabras clave: | Myeloma Phase I trials |
Fecha de publicación: | 24-sep-2019 | Editor: | Springer Nature | Citación: | Bone Marrow Transplantation 55: 419–430 (2019) | Resumen: | This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days −9 and −2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day −5 and tacrolimus (Tk) from −3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2–4 and 3–4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD. | Versión del editor: | http://dx.doi.org/10.1038/s41409-019-0670-6 | URI: | http://hdl.handle.net/10261/203167 | DOI: | 10.1038/s41409-019-0670-6 | ISSN: | 0268-3369 | E-ISSN: | 1476-5365 |
Aparece en las colecciones: | (IBIS) Artículos (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
6
checked on 11-abr-2024
WEB OF SCIENCETM
Citations
6
checked on 27-feb-2024
Page view(s)
147
checked on 17-abr-2024
Download(s)
31
checked on 17-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.